Investigating how PD-1 affects immune cell development in cancer
The effects of PD-1 on tumor-mediated “emergency” myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity
This study is looking at how a protein called PD-1 affects certain immune cells in cancer and whether blocking it can help these cells become better at fighting tumors, which could lead to better treatments for cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10773002 on NIH RePORTER |
What this research studies
This research explores the role of PD-1, a protein that can inhibit immune responses, in the development and function of myeloid cells in the context of cancer. By using mouse models, the study examines how PD-1 influences the production of immune cells during cancer-related stress, particularly focusing on a process called 'emergency myelopoiesis.' The researchers aim to understand how blocking PD-1 can enhance the differentiation of immune cells that fight tumors, potentially leading to improved cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that may benefit from enhanced anti-tumor immunity.
Not a fit: Patients with non-malignant conditions or those not responding to immune therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by enhancing the body's immune response against tumors.
How similar studies have performed: Previous research has shown promising results with PD-1 blocking agents in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Boussiotis, Vassiliki a — Beth Israel Deaconess Medical Center
- Study coordinator: Boussiotis, Vassiliki a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.